Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on April 20, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Director Martin J. Joyce will not seek re-election at Aldeyra’s 2026 annual meeting.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Director Martin J. Joyce will not seek re-election at Aldeyra’s 2026 annual meeting
- Joyce remains on the board until his term expires at the 2026 Annual Meeting
- Departure not related to any disagreement with Aldeyra, reducing concern over disclosed governance conflict
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.